Cargando…
Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation
BACKGROUND: Gastric cancer (GC) represents a malignancy with a multi-factorial combination of genetic, environmental, and microbial factors. Targeting lysosomes presents significant potential in the treatment of numerous diseases, while lysosome-related genetic markers for early GC detection have no...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196375/ https://www.ncbi.nlm.nih.gov/pubmed/37215115 http://dx.doi.org/10.3389/fimmu.2023.1182277 |
_version_ | 1785044338900729856 |
---|---|
author | Wang, Qi Liu, Ying Li, Zhangzuo Tang, Yidan Long, Weiguo Xin, Huaiyu Huang, Xufeng Zhou, Shujing Wang, Longbin Liang, Bochuan Li, Zhengrui Xu, Min |
author_facet | Wang, Qi Liu, Ying Li, Zhangzuo Tang, Yidan Long, Weiguo Xin, Huaiyu Huang, Xufeng Zhou, Shujing Wang, Longbin Liang, Bochuan Li, Zhengrui Xu, Min |
author_sort | Wang, Qi |
collection | PubMed |
description | BACKGROUND: Gastric cancer (GC) represents a malignancy with a multi-factorial combination of genetic, environmental, and microbial factors. Targeting lysosomes presents significant potential in the treatment of numerous diseases, while lysosome-related genetic markers for early GC detection have not yet been established, despite implementing this process by assembling artificial intelligence algorithms would greatly break through its value in translational medicine, particularly for immunotherapy. METHODS: To this end, this study, by utilizing the transcriptomic as well as single cell data and integrating 20 mainstream machine-learning (ML) algorithms. We optimized an AI-based predictor for GC diagnosis. Then, the reliability of the model was initially confirmed by the results of enrichment analyses currently in use. And the immunological implications of the genes comprising the predictor was explored and response of GC patients were evaluated to immunotherapy and chemotherapy. Further, we performed systematic laboratory work to evaluate the build-up of the central genes, both at the expression stage and at the functional aspect, by which we could also demonstrate the reliability of the model to guide cancer immunotherapy. RESULTS: Eight lysosomal-related genes were selected for predictive model construction based on the inclusion of RMSE as a reference standard and RF algorithm for ranking, namely ADRB2, KCNE2, MYO7A, IFI30, LAMP3, TPP1, HPS4, and NEU4. Taking into account accuracy, precision, recall, and F1 measurements, a preliminary determination of our study was carried out by means of applying the extra tree and random forest algorithms, incorporating the ROC-AUC value as a consideration, the Extra Tree model seems to be the optimal option with the AUC value of 0.92. The superiority of diagnostic signature is also reflected in the analysis of immune features. CONCLUSION: In summary, this study is the first to integrate around 20 mainstream ML algorithms to construct an AI-based diagnostic predictor for gastric cancer based on lysosomal-related genes. This model will facilitate the accurate prediction of early gastric cancer incidence and the subsequent risk assessment or precise individualized immunotherapy, thus improving the survival prognosis of GC patients. |
format | Online Article Text |
id | pubmed-10196375 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101963752023-05-20 Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation Wang, Qi Liu, Ying Li, Zhangzuo Tang, Yidan Long, Weiguo Xin, Huaiyu Huang, Xufeng Zhou, Shujing Wang, Longbin Liang, Bochuan Li, Zhengrui Xu, Min Front Immunol Immunology BACKGROUND: Gastric cancer (GC) represents a malignancy with a multi-factorial combination of genetic, environmental, and microbial factors. Targeting lysosomes presents significant potential in the treatment of numerous diseases, while lysosome-related genetic markers for early GC detection have not yet been established, despite implementing this process by assembling artificial intelligence algorithms would greatly break through its value in translational medicine, particularly for immunotherapy. METHODS: To this end, this study, by utilizing the transcriptomic as well as single cell data and integrating 20 mainstream machine-learning (ML) algorithms. We optimized an AI-based predictor for GC diagnosis. Then, the reliability of the model was initially confirmed by the results of enrichment analyses currently in use. And the immunological implications of the genes comprising the predictor was explored and response of GC patients were evaluated to immunotherapy and chemotherapy. Further, we performed systematic laboratory work to evaluate the build-up of the central genes, both at the expression stage and at the functional aspect, by which we could also demonstrate the reliability of the model to guide cancer immunotherapy. RESULTS: Eight lysosomal-related genes were selected for predictive model construction based on the inclusion of RMSE as a reference standard and RF algorithm for ranking, namely ADRB2, KCNE2, MYO7A, IFI30, LAMP3, TPP1, HPS4, and NEU4. Taking into account accuracy, precision, recall, and F1 measurements, a preliminary determination of our study was carried out by means of applying the extra tree and random forest algorithms, incorporating the ROC-AUC value as a consideration, the Extra Tree model seems to be the optimal option with the AUC value of 0.92. The superiority of diagnostic signature is also reflected in the analysis of immune features. CONCLUSION: In summary, this study is the first to integrate around 20 mainstream ML algorithms to construct an AI-based diagnostic predictor for gastric cancer based on lysosomal-related genes. This model will facilitate the accurate prediction of early gastric cancer incidence and the subsequent risk assessment or precise individualized immunotherapy, thus improving the survival prognosis of GC patients. Frontiers Media S.A. 2023-05-05 /pmc/articles/PMC10196375/ /pubmed/37215115 http://dx.doi.org/10.3389/fimmu.2023.1182277 Text en Copyright © 2023 Wang, Liu, Li, Tang, Long, Xin, Huang, Zhou, Wang, Liang, Li and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wang, Qi Liu, Ying Li, Zhangzuo Tang, Yidan Long, Weiguo Xin, Huaiyu Huang, Xufeng Zhou, Shujing Wang, Longbin Liang, Bochuan Li, Zhengrui Xu, Min Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation |
title | Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation |
title_full | Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation |
title_fullStr | Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation |
title_full_unstemmed | Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation |
title_short | Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation |
title_sort | establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196375/ https://www.ncbi.nlm.nih.gov/pubmed/37215115 http://dx.doi.org/10.3389/fimmu.2023.1182277 |
work_keys_str_mv | AT wangqi establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation AT liuying establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation AT lizhangzuo establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation AT tangyidan establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation AT longweiguo establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation AT xinhuaiyu establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation AT huangxufeng establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation AT zhoushujing establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation AT wanglongbin establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation AT liangbochuan establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation AT lizhengrui establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation AT xumin establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation |